Recurrent VTE rates during follow-up in patients with different APA findings (women with estrogen-associated VTE excluded)
| Group/subgroup . | N of patients . | N of VTE events . | Person-years . | Event rate (95% CI) . |
|---|---|---|---|---|
| All patients | 241* | 34 | 510 | 6.7 (4.6-9.3) |
| No APA | 179 | 21 | 386 | 5.4 (3.4-8.3) |
| Men | 119 | 15 | 255 | 5.9 (3.3-9.7) |
| Women | 60 | 6 | 131 | 4.6 (1.7-10.0) |
| Any APA | 62 | 13 | 124 | 10.5 (5.6-17.9) |
| Men | 47 | 11 | 91 | 12.1 (6.0-21.6) |
| Women | 15 | 2 | 32 | 6.3 (0.8-22.6) |
| APA once† | 40 | 7 | 87 | 8.0 (3.2-16.6) |
| Men | 29 | 6 | 62 | 9.7 (3.6-21.1) |
| Women | 11 | 1 | 25 | 4.0 (0.1-22.3) |
| APA twice‡ | 22 | 6 | 37 | 16.2 (6.0-35.5) |
| Men | 18 | 5 | 30 | 16.7 (5.4-38.9) |
| Women | 4 | 1 | 7 | 14.3 (0.4-79.6) |
| ACA only§ | 10 | 1 | 24 | 4.2 (0.1-23.2) |
| IgG only‖ | 6 | 1 | 13 | 7.7 (0.2-42.9) |
| IgM only¶ | 4 | 0 | 10 | 0.0 (0.0-36.9) |
| Anti-β2GP1 only§ | 0 | 0 | 0 | — |
| LA only§ | 41 | 8 | 82 | 9.8 (4.2-19.2) |
| 1 APA type# | 51 | 9 | 105 | 8.6 (3.9-16.3) |
| 2 APA types# | 9 | 4 | 12 | 33.3 (9.1-85.3) |
| 3 APA types# | 2 | 0 | 7 | 0.0 (0.0-52.7) |
| Group/subgroup . | N of patients . | N of VTE events . | Person-years . | Event rate (95% CI) . |
|---|---|---|---|---|
| All patients | 241* | 34 | 510 | 6.7 (4.6-9.3) |
| No APA | 179 | 21 | 386 | 5.4 (3.4-8.3) |
| Men | 119 | 15 | 255 | 5.9 (3.3-9.7) |
| Women | 60 | 6 | 131 | 4.6 (1.7-10.0) |
| Any APA | 62 | 13 | 124 | 10.5 (5.6-17.9) |
| Men | 47 | 11 | 91 | 12.1 (6.0-21.6) |
| Women | 15 | 2 | 32 | 6.3 (0.8-22.6) |
| APA once† | 40 | 7 | 87 | 8.0 (3.2-16.6) |
| Men | 29 | 6 | 62 | 9.7 (3.6-21.1) |
| Women | 11 | 1 | 25 | 4.0 (0.1-22.3) |
| APA twice‡ | 22 | 6 | 37 | 16.2 (6.0-35.5) |
| Men | 18 | 5 | 30 | 16.7 (5.4-38.9) |
| Women | 4 | 1 | 7 | 14.3 (0.4-79.6) |
| ACA only§ | 10 | 1 | 24 | 4.2 (0.1-23.2) |
| IgG only‖ | 6 | 1 | 13 | 7.7 (0.2-42.9) |
| IgM only¶ | 4 | 0 | 10 | 0.0 (0.0-36.9) |
| Anti-β2GP1 only§ | 0 | 0 | 0 | — |
| LA only§ | 41 | 8 | 82 | 9.8 (4.2-19.2) |
| 1 APA type# | 51 | 9 | 105 | 8.6 (3.9-16.3) |
| 2 APA types# | 9 | 4 | 12 | 33.3 (9.1-85.3) |
| 3 APA types# | 2 | 0 | 7 | 0.0 (0.0-52.7) |
Does not include the 12 patients who had a positive qualitative D-dimer at enrollment and therefore did not stop anticoagulants.
Includes patients who were tested for any APA once (n = 25), twice (n = 66), or 3 times (n = 154); the same test was not performed more than twice.
Only includes patients who had the same APA on 2 occasions (consistent with the Sapporo-Sydney criteria for diagnosis of antiphospholipid syndrome).
Test may have been positive on 1 or 2 occasions.
Highest anticardiolipin IgG antibody in each patient: 23, 31, 28, 24, 24, and 24 units (recurrent VTE).
Highest anticardiolipin IgM antibody in each patient: 35, 32, 54, and 48 units.
Tests may have been positive on the same or different occasions. Event rate for patients with either 2 or 3 APA types was 21.1 (95% CI, 5.7-53.9) per 100 person-years.